News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
finance.yahoo.com Market update
Argenx stock surged Monday after its blockbuster autoimmune drug, Vyvgart, showed promise in patients with inflammatory diseases. Continue Reading
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
argenx SE Study met primary endpoint of mean Total Improvement Score (TIS) at Week 52 in the combined study population of IMNM and DM patients (p=0.0011) Patient improvements observed early and sustained throughout study; consistent treatment effect across IMNM and DM First Phase 3 …
argenx SE (NASDAQ:ARGX) agreed to buy Forte Biosciences, Inc. (NASDAQ:FBRX) for about $2.2 billion in cash, paying $77 a share, a roughly 40% premium to Forte's Friday closing price. The deal adds Forte's experimental drug FB102, which analysts describe as a first-in-class anti-CD122 antibody, …
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Recent share performance and business profile Without a single clear news event driving headlines, …
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. argenx stock has delivered a strong long term return over the past five years, yet the current valuation checks and recent acquisition plans raise questions about how …
Halozyme Therapeutics HALO reported second-quarter 2026 adjusted earnings of $2.28 per share, which comprehensively beat the Zacks Consensus Estimate of $1.82. Earnings rose 48.1% year over year. Total revenues in the second quarter increased 48% year over year to $481 million. Revenues also surpassed …
argenx SE August 6, 2026 – 7:45 AM ET Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company today announced that Avena Merger Sub Inc. ("Purchaser"), a wholly-owned subsidiary of argenx BV ("argenx"), has commenced a tender offer to …
Investors might want to bet on argenex SE (ARGX), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. …
Baron Capital, an investment management company, released its Q2 2026 investor letter for the "Baron Health Care Fund". A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 …
3d illustration inflation and deflation graph by Deepadesigns via Shutterstock Argenx (ARGX) announced the acquisition of Forte Biosciences (FBRX) at $77 per share on July 27. FBRX saw significant price movement beginning June 29, weeks before the public announcement. Both FBRX and ARGX exhibited …
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has argenex SE (ARGX) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the …
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. argenx SE has entered into a definitive agreement to acquire Forte Biosciences through a cash tender offer. The boards of both companies have approved the transaction, which …
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. argenx (ENXTBR:ARGX) is back in focus after agreeing to acquire Forte Biosciences in an all cash deal valued at about US$2.2b, centered on Forte's …
argenx has entered a definitive agreement to acquire Forte Biosciences for approximately $2.2bn in total equity value. Approved by both companies' boards of directors, the transaction is expected to close in the third quarter of 2026, contingent upon standard closing conditions. The main asset …
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. argenx stock has delivered a very strong 202.6% return over the past five years, yet its current valuation checks point to a more mixed …
(RTTNews) - Today's top biotech gainers include Entera Bio, following an oversubscribed private placement financing; Gossamer, which is progressing toward a planned Seralutinib NDA submission in September; First Tracks, which has been firing on all cylinders since its Nasdaq debut; and Forte Biosciences, following …
Beauty pharmaceutical research by Chokniti-Studio via Shutterstock Forte Biosciences (FBRX) ripped higher on Monday after the Dutch immunology giant, Argenx (ARGX), announced a definitive agreement to acquire it for $2.2 billion. The all-cash transaction is expected to close in the third quarter of 2026 …
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Argenx will acquire Forte Biosciences, the developer of an autoimmune disease drug that's shown early promise, in a deal worth up to …
Stock chart with green arrow moving up ©Adobe Stock Images Forte Biosciences (NASDAQ:FBRX) shares climbed 39.2% in pre-market trading after argenx (NASDAQ:ARGX) announced a definitive agreement to acquire the clinical-stage biotechnology company in an all-cash transaction valued at approximately $2.2 billion. Under the terms …
Medical researcher in gloves using a tablet ©Adobe Stock Images Argenx NV ADR (NASDAQ:ARGX) has agreed to acquire Forte Biosciences Inc (NASDAQ:FBRX) in a transaction valued at approximately $2.2 billion, expanding its portfolio of autoimmune disease treatments as it looks to build new growth …
[Colorful collage. Hands holding orange and blue puzzle pieces representing corporate merger and innovation] * argenx SE (ARGX [https://seekingalpha.com/symbol/ARGX]) to acquire [https://seekingalpha.com/pr/20595280-argenx-to-acquire-forte-biosciences-inc-adding-first-in-class-anti-cd122-antibody-fb102-to] Forte Biosciences (FBRX [https://seekingalpha.com/symbol/FBRX]) for $77 per share in cash, valuing the transaction at ~$2.2B. * The acquisition will add Forte’s lead …
(RTTNews) - Argenx (ARGX), an immunology company, and Forte Biosciences, Inc. (FBRX),a clinical-stage biopharmaceutical company on Monday announced that they have entered into a definitive agreement under which Argenx will acquire Forte Biosciences for $77 per share in cash, representing a total equity value …
Transaction builds on argenx’s prior strategic investment in Forte Biosciences and reflects a disciplined approach to accessing novel biology that can fuel long-term growthFB102 Phase 1b studies in vitiligo and celiac disease validate CD122 biology and pipeline-in-a-product potential to address diseases with high unmet …
* argenx SE press release [https://seekingalpha.com/pr/20592469-argenx-reports-half-year-2026-financial-results-and-provides-second-quarter-business-update] (ARGX [https://seekingalpha.com/symbol/ARGX]): Q2 GAAP EPS of $7.32 beats by $1.12. * Revenue of $1.52B (+60.0% Y/Y) beats by $90M. * Cash flow from operating activities for the six months ended June 30, 2026 was $0.7 billion compared to …
argenx SE Strong second quarter performance with $1.5 billion in global product net sales, representing 60% year-over-year growth and 17% quarter-over-quarter growth Successfully launched VYVGART and VYVGART Hytrulo in anti-AChR antibody negative ("seronegative") gMG, expanding patient reach to all gMG serotypes Registrational autoimmune myositis …
Search by ticker symbol or company name and select a result to open its chart.